Abstract:Telomerase is expressed in more than 85% of cancer cells. Tumor cells with metastatic potential may have a high telomerase activity, allowing cells to escape from the inhibition of cell proliferation due to shortened telomeres. Human telomerase primarily consists of two main components: hTERT, a catalytic subunit, and hTR, an RNA template whose sequence is complimentary to the telomeric 5'-dTTAGGG-3' repeat. In humans, telomerase activity is typically restricted to renewing tissues, such as germ cells and stem cells, and is generally absent in normal cells. While hTR is constitutively expressed in most tissue types, hTERT expression levels are low enough that telomere length cannot be maintained, which sets a proliferative lifespan on normal cells. However, in the majority of cancers, telomerase maintains stable telomere length, thereby conferring cell immortality. Levels of hTERT mRNA are directly related to telomerase activity, thereby making it a more suitable therapeutic target than hTR. Recent data suggests that stabilization of telomeric G-quadruplexes may act to indirectly inhibit telomerase action by blocking hTR binding. Telomeric DNA has the propensity to spontaneously form intramolecular G-quadruplexes, four-stranded DNA secondary structures that are stabilized by the stacking of guanine residues in a planar arrangement. The functional roles of telomeric G-quadruplexes are not completely understood, but recent evidence suggests that they can stall the replication fork during DNA synthesis and inhibit telomere replication by preventing telomerase and related proteins from binding to the telomere. Long-term treatment with G-quadruplex stabilizers induces a gradual reduction in the length of the G-rich 3' end of the telomere without a reduction of the total telomere length, suggesting that telomerase activity is inhibited. However, inhibition of telomerase, either directly or indirectly, has shown only moderate success in cancer patients. Another promising approach of targeting the telomere is the use of guanine-rich oligonucleotides (GROs) homologous to the 3' telomere overhang sequence (T-oligos). T-oligos, particularly a specific 11-base oligonucleotide (5'-dGTTAGGGTTAG-3') called T11, have been shown to induce DNA damage responses (DDRs) such as senescence, apoptosis, and cell cycle arrest in numerous cancer cell types with minimal or no cytostatic effects in normal, non-transformed cells. As a result, T-oligos and other GROs are being investigated as prospective anticancer therapeutics. Interestingly, the DDRs induced by T-oligos in cancer cells are similar to the effects seen after progressive telomere degradation in normal cells. The loss of telomeres is an important tumor suppressor mechanism that is commonly absent in transformed malignant cells, and hence, T-oligos have garnered significant interest as a novel strategy to combat cancer. However, little is known about their mechanism of action. In this review, we discuss the current understanding of how T-oligos exert their antiproliferative effects in cancer cells and their role in inhibition of telomerase. We also discuss the current understanding of telomerase in cancer and various therapeutic targets related to the telomeres and telomerase.

Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.

Tankyrase1-mediated Poly(adp-Ribosyl)ation of TRF1 Maintains Cell Survival after Telomeric DNA Damage.

Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding

Distinct CRC-associated APC mutations dictate response to Tankyrase inhibition.

Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability

Effect of Suppressing Tankyrases on Canonical Wnt Pathway: A New Target for the Treatment of Cancer

The Discovery Of Small Molecule Inhibitors Of Tankyrases 1 And 2, Which Modulate Axin Homeostasis And Inhibit Wnt Signaling In Vivo

Akt Regulates TPP1 Homodimerization and Telomere Protection

Abstract LT07: Signalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)

Mutual reinforcement between telomere capping and canonical Wnt signalling in the intestinal stem cell niche

Inhibition of telomerase limits the growth of human cancer cells

Tankyrase Disrupts Metabolic Homeostasis and Promotes Tumorigenesis by Inhibiting LKB1-AMPK Signalling

Modulation Of Beta-Catenin Signaling By The Inhibitors Of Map Kinase, Tyrosine Kinase, And Pi3-Kinase Pathways

Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins.

Telomerase inhibitors: targeting the vulnerable end of cancer?

Treating Cancer by Targeting Telomeres and Telomerase

Crossroads of telomere biology and anticancer drug discovery

Abstract 1807: New strategies to target the pseudokinase receptor PTK7 in the Wnt pathway

Tankyrases/β-catenin Signaling Pathway As an Anti-proliferation and Anti-metastatic Target in Hepatocarcinoma Cell Lines.

Insights into the Biomedical Effects of Carboxylated Single-Wall Carbon Nanotubes on Telomerase and Telomeres.

Discovery of Novel Inhibitor for WNT/-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening